NEW YORK (GenomeWeb) – Genentech is working with health regulators in the US and EU to garner their go ahead for a master basket study protocol, called iMATRIX, which the company plans to use to quickly evaluate drugs across its oncology portfolio for pediatric use.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.